Degos disease – malignant atrophic papulosis or cutaneointestinal lethal syndrome: rarity of the disease by Pirolla, Eduardo et al.
Degos disease – malignant atrophic
papulosis or cutaneointestinal lethal
syndrome: rarity of the disease
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Pirolla, Eduardo, Felipe Fregni, Irene K Miura, Antonio Carlos
Misiara, Fernando Almeida, and Esdras Zanoni. 2015. “Degos
disease – malignant atrophic papulosis or cutaneointestinal
lethal syndrome: rarity of the disease.” Clinical and Experimental
Gastroenterology 8 (1): 141-147. doi:10.2147/CEG.S59794. http://
dx.doi.org/10.2147/CEG.S59794.
Published Version doi:10.2147/CEG.S59794
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:15034929
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
© 2015 Pirolla et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Clinical and Experimental Gastroenterology 2015:8 141–147
Clinical and Experimental Gastroenterology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
141
E x p E rt  O p i n i O n
open access to scientific and medical research
Open Access Full text Article
http://dx.doi.org/10.2147/CEG.S59794
Degos disease – malignant atrophic papulosis  
or cutaneointestinal lethal syndrome: rarity  
of the disease
Eduardo pirolla1
Felipe Fregni1
irene K Miura2
Antonio Carlos Misiara3
Fernando Almeida3
Esdras Zanoni3
1Spaulding rehabilitation network 
research Laboratory, Harvard Medical 
School, Boston, MA, USA; 2University 
of São paulo, Sirio Libanes Hospital, 
São paulo, Brazil; 3Sirio Libanes 
Hospital, São paulo, Brazil
Correspondence: Eduardo H pirolla 
Spaulding rehabilitation network 
research Laboratory, 96 13th Street, 
Charlestown, Boston, 02124, MA, USA 
Email eduardopirolla@gmail.com
Background: Degos disease is a very rare syndrome with a rare type of multisystem vascul-
opathy of unknown cause that affects the skin, gastrointestinal tract, and central nervous system. 
Other organs such as the kidneys, lungs, pleura, liver, heart, and eyes, can also be involved.
Objective: To highlight the incidence of Degos disease with regard to age and sex, discuss the 
necessity of its accurate and early diagnosis, and demonstrate the most current techniques for 
its diagnosis; to discuss whether early therapeutic intervention can impact patient prognosis; 
and to present a literature review about this disease.
Design: With a retrospective, observational, nonrandomized trial, we described the evolution 
of the different forms of Degos disease and referenced the literature.
Data sources: Research on rare documented cases in the literature, including two cases of 
potentially lethal form of the disease involving the skin and gastrointestinal system and, pos-
sibly, the lungs, kidneys, and central nervous system. A case of the benign form of the disease 
involving the skin was observed by the authors.
Main outcome measures: Differences between outcomes in patients with the cutaneointestinal 
form and skin-only form of the disease. There was one fatal outcome. We reviewed possible 
new approaches to diagnosis and treatment.
Results: The study demonstrated the rapid evolution of the aggressive and malignant form of the 
disease. It also described newly accessible Phase I diagnostic tools being currently researched 
as well as new therapeutic approaches.
Limitation: The rarity of the disease, with only eleven cases throughout the literature.
Conclusion: The gastrointestinal form of Degos disease can be lethal. Its vascular etiology has 
finally been confirmed; however, new and more accurate early diagnostic modalities need to be 
developed. There are new therapeutic possibilities, but the studies of them are still in the early 
stages and have not yet shown the full effectiveness of these new therapies.
Keywords: multisystem vasculopathy, diagnosis, lethal, gastrointestinal, Degos disease
Introduction
Degos disease most frequently presents in white male teenagers, with the initial symp-
tom being skin lesions on the trunk (Figure 1). Sometimes, within days, the patient 
presents with generalized acute abdominal pain and fever. Patients in this situation are 
frequently treated with surgery (exploratory laparotomy). Patients experience frequent 
vomiting and abdominal distension that does not improve after surgery. Weight loss 
at an average of 6–10 kg per month is common. A repeat laparotomy is frequently 
performed because of intestinal occlusion by adherences or acute peritonitis. Persistent 
high fevers, abdominal pain, and gastroparesis are very common in these cases.
Clinical and Experimental Gastroenterology 2015:8
Figure 1 initial skin lesions in Degos disease.
Figure 2 White/yellowish lesions and ileal, duodenal, and gastric perforations.
Note: (A) Duodenal perforation. (B) Gastric perforation.
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At the time of admission, fever (100.4°F–104.0°F), 
normal blood pressure, and sinus tachycardia are frequent. 
 Peritonitis and septicemia should be suspected. In progres-
sive conditions of the disease, multiple lesions with a papular 
aspect are observed in the thorax wall, abdominal wall, and 
limbs.
Blood tests reveal an elevated white blood cell count 
(normally of more than 30,000 cells/mm3) and low levels of 
hemoglobin and platelets because of infection. Blood gases 
show respiratory alkalosis with concomitant metabolic aci-
dosis in most cases.
Chest and abdominal computerized tomography (CT) 
can reveal pleural effusion in the lower lungs fields and free 
liquid in the abdominal cavity with an edematous bowel 
aspect. Paralytic ileum can be present.
Laparotomy is always indicated and can show lesions 
consisting of white and yellowish or pearly-rose patches 
( Figure 2A) with a hyperemic rim throughout the bowel, 
mainly in the gastrointestinal tract. One or more points of 
perforation can commonly be observed in the jejunum, ileum, 
and colon, resulting in intestinal resections (Figure 2B).
Microscopic examination can reveal poor lymphomono-
nuclear infiltrate and no granulomatous process, vasculitis, 
or neoplastic involvement.
A second-look operation is commonly performed 
48 hours after the first laparotomy because of the frequent 
occurrence of new abdominal pain and an improvement in 
the inflammatory conditions. A skin biopsy is important for 
the diagnosis of Degos disease and will exhibit epidermal 
atrophy and dermal sclerosis with or without vasculitis. 
However, the histological findings of the intestinal and skin 
lesion biopsies may be inconclusive.
The diagnosis of inflammatory bowel diseases, such as 
Crohn’s disease, frequently requires discussion of the case 
by multiple doctors. Corticoids, such as methylprednisolone, 
are the first drug that doctors use in these patients.
Many repeat laparotomies are performed because of 
abscesses observed on control CTs.
A dermatological evaluation of skin lesions from multiple 
body locations (Figures 3 and 4) may encourage new skin 
microscopic examinations and may reveal an expressive 
papillary dermal sclerosis and thrombosis in the papillary 
dermis and in the vessels below the lesions.
With these histopathological findings and clinical/surgi-
cal aspects patients can be diagnosed with Degos disease. 
Antiplatelet therapy (acetylsalicylic acid) may be initiated 
and can be given in combination with steroid therapy. 
 Pentoxifylline and heparin should also be given. Interleukin, 
interferon and infliximab can also be added to the treatment. 
As studies have shown that vasculitis is the initial skin condi-
tion of Degos disease. The objective of those research models 
was to select drugs that block the deleterious autoimmune 
response in the blood vessels (Figure 5).1
Clinical and Experimental Gastroenterology 2015:8
Figure 3 Skin lesions, typical aspect with necrosis, fibrin and deep lesions.
Figure 4 Skin lesions, characteristic aspect of deep lesions and diffuse distribution.
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New perforations and bowel necrosis can occur, mak-
ing new resections, enterectomies, and stomas necessary 
(Figures 6 and 7).
Microscopic examination will reveal diffuse transmural 
ulcerations and punctate perforations associated with an  occlusive 
fibrosis of the medium- and small-diameter arteries and veins. 
Vessels are often occluded by thrombosis.
Uncontrollable septicemia and persistent gastrointestinal 
bleeding associated with renal failure and cerebral vascular 
lesions are the most common causes of death in patients with 
Degos disease.
The median period of survival for these patients is no 
longer than 6 months.
Results
Between June 1, 1998, and December 23, 2008, three cases 
of Degos disease were recorded, one case of the cutaneous 
or benign form and two cases of the cutaneous intestinal 
or malignant form. In 2013, a retrospective study of Degos 
disease cases was conducted, which revealed a permanent 
lethality of the malignant form of the disease. It also showed 
a favorable evolution, with greater than a 20% survival rate 
of the benign form of the disease.2
The retrospective study demonstrated the rapid evolu-
tion of the aggressive and malignant form of the disease, as 
well as newly accessible diagnostic tools, diagnostic tools 
currently being researched in Phase I trials, and new thera-
peutic approaches.
Limitation
The main limitation to this study is based on the rarity of 
the disease, with only eleven cases described throughout the 
world medical literature.
Discussion and systematic review
Degos disease, also known as Köhlmeier–Degos disease and 
malignant atrophic papulosis (MAP), is a rare vasculopathy of 
unknown cause that mainly involves the skin, gastrointestinal 
tract, central nervous system, and, occasionally, other organs. It 
was first named by Degos et al3 in 1942, but a case was reported 
in 1941 by Köhlmeier,4 who interpreted it as thromboangiitis 
obliterans of the mesenteric vessels. Although this disease 
usually affects young people, with an age of onset between 
20 and 40 years, it may present at any age, even as early as 
8 months.5,6 The disease has a male predominance (3:1), and 
sporadic cases of familial involvement have been recorded.5–9 
The involvement of the gastrointestinal tract and other organs 
has been noted in approximately 60% of reported cases.10
Degos disease is a truly systemic illness, and at autopsy, 
lesions may be found in multiple sites, including the heart, 
lungs, kidneys, bladder, eyes, liver, and genital and oral 
mucosa.11–16 However, in a subgroup of patients, the disorder 
may pursue a benign course involving only the skin for many 
years.15 Skin lesions are usually the first sign of the disease.5 
The disease has been reported to be purely cutaneous in 
37% of patients.17 Clinically, one sees pink- to rose-colored 
papules that may appear telangiectatic and are in different 
stages of development. Early lesions are slightly darker, may 
have an elevated border, and exhibit a central porcelain-white 
depression. The lesions are asymptomatic (except in a few 
cases in which they have appeared pruritic), benign and pre-
dominantly appear on the trunk and extremities.5,18
The lesions affect the bowel in approximately 
47% of cases. Intestinal symptoms are variable, although 
Clinical and Experimental Gastroenterology 2015:8
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Figure 5 An experimental mouse model of autoimmune pancreatitis, which is a t-cell-mediated disease.
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any portion of the intestinal system (from the oral cavity 
to the anus) may be involved, and the small bowel is pre-
dominantly affected. Lesions of the gastrointestinal tract 
are most often associated with skin involvement.15,16,18 In 
rare cases, a bowel injury may precede cutaneous signs, 
hampering the diagnosis.14,19 Some patients are asymp-
tomatic, but others may complain of indigestion, diarrhea, 
constipation, and symptoms of gastroparesis or abdominal 
distension.15,20
Many patients are asymptomatic, and abdominal 
involvement may be uncovered by systematic  investigations, 
 including endoscopy (visualizing white, yellowish, or pearly-
rose patches with a hyperemic rim resembling the skin lesions 
but larger in size), laparoscopy (showing a comparable 
aspect on parietal and visceral peritoneum), and angiography 
 (showing multiple stenoses of branches of the inferior mesen-
teric artery and hypovascular zones on delayed pictures).18,21–23 
Multiple red inflammatory and white atrophic maculae can be 
observed on the serosa of the small and large intestines, and 
a section of the removed specimen can show acute inflamma-
tion and ulceration of the mucosa with surrounding intense 
congestion.15 Of greater importance, a small infarction of the 
Clinical and Experimental Gastroenterology 2015:8 submit your manuscript | www.dovepress.com
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intestine may develop and cause perforation and resultant 
peritonitis.24,25 To avoid fistulous problems, biopsies of the 
bowel wall should never be taken. Instead, biopsies of the 
parietal peritoneum lesions should be taken.18
Neurological involvement occurs in 19% of cases.16,26–28 
The manifestation of neurological involvement is highly vari-
able, but hemiparesis with or without aphasia, monoplegia, 
tetraplegia, and cranial nerve involvement have been found. 
Cases of ascending polyradiculitis or myelomalacia have 
been reported. Headache, mental dysfunction, and weakness 
of the limbs are also common. Sometimes, injuries of the 
whole eye may be observed.16,28
The diagnosis of Degos disease is based on the following 
clinicopathologic finding: many papules, 2–5 mm in dia-
meter, with the classic porcelain-white centers characteristic 
of Degos disease. Some cases have exhibited different clinical 
morphologies that corresponded to the evolutionary stages 
of the papules originally described by Degos. Histologically, 
those patients exhibited a preeminent interface reaction with 
squamatization of the dermo–epidermal junction, melanin 
incontinence, epidermal atrophy, and a developing zone of 
papillary dermal sclerosis that resembled the early stages of 
lichen sclerosus et atrophicus, in miniature. This interface 
reaction was invariably confined to the central portion of 
the punch biopsy specimen, corresponding to the central 
porcelain-white area observed clinically. Additional features 
of fully developed papules included a prominent lympho-
cytic vasculitis affecting the venules, a mild periadnexal 
infiltrate of neutrophils and/or eosinophils, and interstitial 
mucin  deposition. According to Harvell et al, these inflam-
matory cells are sometimes absent.29 In late-stage papules, 
the porcelain-white areas are more developed and the lesions 
are flattened. Histologically, the degree of inflammation 
was generally sparse, and the overall picture mirrored the 
classic histological description of Degos disease with a 
central roughly wedge-shaped zone of sclerosis surrounded 
by atrophic epidermis and hyperkeratotic compact stratum 
corneum.30 Skin lesions typically occur on the trunk and 
limbs. The palm, soles, face, and scalp are characteristically 
free of lesions.16,28
The accurate etiology of Degos disease is still unclear, 
although viral, genetic, and immune mechanisms and 
an anomalous fibrinolysis have all been implicated. The 
pathogenesis of Degos disease is still under discussion, 
but primary endothelial swelling with vascular thrombosis 
leading to tissue infarction has been proposed. The cause of 
the initial vascular injury is unknown, but a mononuclear 
vasculitis seems to be the favored mechanism.28 It is pos-
sible for Degos disease to be associated with other systemic 
diseases.31 Its differential diagnosis is poor, as the cutaneous 
lesions are pathognomonic. Yet systemic lupus erythemato-
sus and inflammatory bowel disease may occasionally be 
discussed.32,33
Approximately 15% of Degos disease patients exhibit 
long-term survival, with the disease often limited to the 
skin and with no history of catastrophic bowel or central 
nervous system involvement. When there is multiple organ 
involvement, the disease results in death within 2–3 years.15 
The course of the disease may be as long as 20 years, but 
once intestinal lesions have appeared, death usually occurs 
within a few months. The most common causes of death 
are peritonitis (61%), central nervous system complications 
(18%), and pleuritis and/or pericarditis (16%).17
Figure 6 Diffuse ileal and colonic lesions and perforations.
Figure 7 Diffuse ileal and colonic lesions and perforations (arrows).
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There is no proven effective treatment for patients with 
systemic involvement.23 Treatment with plasma change, corti-
costeroids, immunosuppressants, or antiinflammatory drugs has 
been ineffective in reversing the course of this disease when sys-
temic involvement is present.15,34,35 Some authors have reported a 
good response to antiplatelet therapy.10,11,36,37 A publication from 
Japan in January 2013 showed the expression of stromal cell-
derived factor (SDF)-1/CXCL12 in Degos disease. Secretory 
activity by stromal and endothelial cells of the bone marrow 
activates SDF-1/CXCL12 of megakaryocyte precursors and is 
responsible for the costimulation of platelet activation. Patients 
with Degos disease demonstrated a high level of secretion of 
SDF-1/CXCL12 inflammatory cells. This cell type was located 
in the perivascular, intravascular, and perineural tissue. These 
results support the theory that Degos disease is an endothelial 
disease.38,39
Conclusion
The gastrointestinal form of Degos disease remains a serious 
and lethal disease. The vascular etiology of this disease has 
finally been confirmed; however, new and more accurate 
early diagnostic modalities need to be developed. There are 
new therapeutic possibilities; however, studies of new treat-
ments are still in the early stages and the full effectiveness 
of those treatments has not been shown.
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